Argos Therapeutics today announced the declaration of a dissertation in the February edition of Clinical Immunology, repetition certain immune response, safety and manufacturing data for its AGS-004 immunotherapy for HIV. AGS-004 is a product of the Company’s Arcelis™ technology, and is a personalized, RNA-loaded dendritic cell-based immunotherapy that is third edition by the editors of the red white and blue heritage dictionary. copyright 2003 matched to each patient’s unique HIV viral burden. The drama details a clinical study in which AGS-004 was evaluated in type-1 HIV-infected adults who were being treated with antiretroviral therapy (ART).
More: - Read the rest here